Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 3 miu - powder for injection - 3 miu - active: interferon alfa-2a 3 miu excipient: albumin sodium chloride water for injection

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 4.5 miu - powder for injection - 4.5 miu - active: interferon alfa-2a 4.5 miu excipient: albumin sodium chloride water for injection

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 6 miu - powder for injection - 6 miu - active: interferon alfa-2a 6 miu excipient: albumin sodium chloride water for injection

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 9 miu - powder for injection - 9 miu - active: interferon alfa-2a 9 miu excipient: albumin sodium chloride water for injection

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 30 miu/ml (final fill volume, 0.72 ml, includes a 20 % fill overage); ribavirin 200mg;   - combination - 18 miu/0.6 ml, 200 mg - active: interferon alfa-2a 30 miu/ml (final fill volume, 0.72 ml, includes a 20 % fill overage) excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection active: ribavirin 200mg   excipient: ethylcellulose as aqueous dispersion (solids) hypromellose as component of opadry 03a14309 pink iron oxide red as component of opadry 03a14309 pink iron oxide yellow as component of opadry 03a14309 pink magnesium stearate maize starch microcrystalline cellulose purified talc as component of opadry 03a14309 pink sodium starch glycolate starch titanium dioxide as component of opadry 03a14309 pink triacetin

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 6 miu/ml; ribavirin 200mg;   - combination - 3miu/0.5ml, 200mg - active: interferon alfa-2a 6 miu/ml excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection active: ribavirin 200mg   excipient: ethylcellulose hypromellose as component of opadry 03a14309 pink iron oxide red as component of opadry 03a14309 pink iron oxide yellow as component of opadry 03a14309 pink magnesium stearate maize starch microcrystalline cellulose purified talc as component of opadry 03a14309 pink sodium starch glycolate starch titanium dioxide as component of opadry 03a14309 pink triacetin

Irska - angleščina - HPRA (Health Products Regulatory Authority)

roche products limited - interferon alfa-2a - solution for injection - 18miu/0.6m %v/v

Irska - angleščina - HPRA (Health Products Regulatory Authority)

roche products limited - interferon alfa-2a - solution for injection - 18 miu/0.5 %v/v

Združene države Amerike - angleščina - NLM (National Library of Medicine)

merck sharp & dohme llc - interferon alfa-2b (unii: 43k1w2t1m6) (interferon alfa-2b - unii:43k1w2t1m6) - interferon alfa-2b 38 ug in 1 ml - intron® a is indicated for the treatment of patients 18 years of age or older with hairy cell leukemia. intron a is indicated as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease but at high risk for systemic recurrence, within 56 days of surgery. intron a is indicated for the initial treatment of clinically aggressive (see clinical pharmacology ) follicular non-hodgkin's lymphoma in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older. efficacy of intron a therapy in patients with low-grade, low-tumor burden follicular non-hodgkin's lymphoma has not been demonstrated. intron a is indicated for intralesional treatment of selected patients 18 years of age or older with condylomata acuminata involving external surfaces of the genital and perianal areas (see dosage and administration ). the use of this product in adolescents has not been studied. intron a is indicated for the treatment of select

Združene države Amerike - angleščina - NLM (National Library of Medicine)

merck sharp & dohme corp. - peginterferon alfa-2b (unii: g8rgg88b68) (interferon alfa-2b - unii:43k1w2t1m6) - peginterferon alfa-2b 50 ug in 0.5 ml - pegintron® , as part of a combination regimen, is indicated for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease. - pegintron in combination with ribavirin and an approved hepatitis c virus (hcv) ns3/4a protease inhibitor is indicated in adult patients with hcv genotype 1 infection (see labeling of the specific hcv ns3/4a protease inhibitor for further information). - pegintron in combination with ribavirin is indicated in patients with genotypes other than 1, pediatric patients (3-17 years of age), or in patients with genotype 1 infection where use of an hcv ns3/4a protease inhibitor is not warranted based on tolerability, contraindications or other clinical factors. pegintron monotherapy should only be used in the treatment of chc in patients with compensated liver disease if there are contraindications to or significant intolerance of ribavirin and is indicated for use only in previously untreated adult patients. combination therapy provides substantially better respons